Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea.
OBJECTIVE
The retrospective study was performed to assess the efficacy and toxicity profiles of sunitinib in Korean patients with metastatic renal cell carcinoma (RCC).


METHODS
Between January 2005 and December 2008, 76 Korean patients with recurrent/metastatic RCC who received sunitinib were retrospectively reviewed. The primary end point was progression-free survival and the secondary end points were overall survival and response rate. We also assessed the toxicities associated with sunitinib treatment.


RESULTS
Of the 76 patients, 69 (90.1%) were diagnosed with clear cell RCC. The median progression-free survival and overall survival were 7.2 and 22.8 months, respectively in overall patients. Sixty-two patients (81.6%) received 50 mg 4 week and 2 week off schedule, and 14 patients (18.4%) received 37.5 mg daily on a daily continuous schedule. The objective response rate and disease control rate were 27.6% and 84.2%, respectively. A dose reduction or reduction in dose due to adverse events occurred in 76% of the patients, whereas 11% of the patients had discontinued treatment. Other common laboratory abnormalities were increased serum creatinine (75.6%), elevated alanine aminotransferase (71.0%), neutropenia (61.8%), anemia (69.7%), and increased aspartate aminotrasferase (53.3%). Grade 3/4 toxicities occurred as follows: thrombocytopenia (38.2%), fatigue (10.5%), stomatitis (10.5%), and hand-foot syndrome (9.2%).


CONCLUSIONS
Our results indicate that sunitinib treatment is effective and tolerable for ecurrent/metastatic RCC patients in Korea. Further studies with prognostic or biochemical factors are needed to clarify the different toxicity profiles of this study.
Hong
Min Hee
MH
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Kim
Hyo Song
HS
Kim
Chan
C
Ahn
Jung Ryun
JR
Chon
Hong Jae
HJ
Shin
Sang-Joon
SJ
Ahn
Joong-Bae
JB
Chung
Hyun Cheol
HC
Rha
Sun Young
SY
Mol Cancer Ther. 2003 May;2(5):471-8
12748309
Urol Clin North Am. 2003 Nov;30(4):843-52
14680319
Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10595-9
8855223
JAMA. 2006 Jun 7;295(21):2516-24
16757724
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
Cancer Res Treat. 2008 Dec;40(4):211-3
19688133
J Clin Oncol. 2007 Mar 1;25(7):884-96
17327610
Nat Genet. 1994 May;7(1):85-90
7915601
Dis Colon Rectum. 2007 Dec;50(12):2180-7
17963003
J Clin Oncol. 2006 May 10;24(14):2137-50
16682732
Clin Cancer Res. 2008 Jan 1;14(1):8-13
18172246
Cutan Ocul Toxicol. 2008;27(4):311-5
19037763
N Engl J Med. 2007 Jan 11;356(2):115-24
17215529
CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
15661684
J Clin Oncol. 2004 Feb 1;22(3):454-63
14752067